TITLE:
Blocking Translation of Oncogenic mRNA
AUTHORS:
Kelvin N. Christie
KEYWORDS:
Antisense Oligonucleotides, Ribozymes, Phosphorothioate, Double-Stranded RNA-Mediated Interference, Nucleases
JOURNAL NAME:
Journal of Cancer Therapy,
Vol.14 No.6,
June
16,
2023
ABSTRACT: Double-stranded
RNA-mediated interference (RNAi), antisense oligonucleotides (ASO), and
ribozymes have excellent specificity to their target oncogenic mRNA. They also
seem to show great promise when it comes to treating cancer. The problem is
that RNAi, ASO, and ribozymes have poor
stability and are constantly being degraded by nucleases. Researchers have made some
efforts to increase antisense oligonucleotides’ stability by creating
phospharimidate and Phosphorothioate. Currently, ribozymes, antisense
oligonucleotides, and (RNAi) are the three main methods used to target RNA.
These methods are currently undergoing clinical trials for the purpose of
focusing on specific RNAs involved in disorders like cancer and
neurodegeneration. In fact, ASOs that target amyotrophic lateral sclerosis and
spinal muscular atrophy have produced promising results in clinical trials. The
formation of chemical alterations that boost affinity and selectivity while
reducing noxiousness owing to off-target impacts are two benefits of ASOs.
Another benefit is increased affinity. With a focus on RNAi and ASOs, this
review illustrated the main therapeutic strategies of RNA therapy now in use.